Dr. Dreicer on Newer Prostate Therapy Survival Benefits

Robert Dreicer, MD
Published: Wednesday, Mar 30, 2011

Robert Dreicer, MD from the Taussig Cancer Institute, explains that the survival benefits observed for abiraterone acetate (Zytiga) and sipuleucel-T (Provenge) are both in the range of 4 months. Additionally, post docetaxel the agent cabazitaxel also improves survival. Since all of these agents improve survival the questions becomes how do you use them, should you combine, and in which population.
 
Robert Dreicer, MD from the Taussig Cancer Institute, explains that the survival benefits observed for abiraterone acetate (Zytiga) and sipuleucel-T (Provenge) are both in the range of 4 months. Additionally, post docetaxel the agent cabazitaxel also improves survival. Since all of these agents improve survival the questions becomes how do you use them, should you combine, and in which population.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Genitourinary Malignancies™Sep 29, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x